ESMO 2019 Congress | OncologyPRO

Abstract 4947

Background

25-hydroxyvitamin D and active analogues have shown to inhibit growth of pancreatic cancer (PC) cell lines. However, studies describing the relationship between serum levels of vitamin D and survival in PC patients have shown conflicting results. The aim of the study was to evaluate the association between pre-treatment 25-hydroxyvitamin D levels and survival in Danish patients with PC.

Methods

In the prospective BIOPAC study (NCT03311776), the pre-treatment serum 25-hydroxyvitamin D (S-25(OH)D) concentrations were determined in 1233 patients with PC included from July 2008 to December 2018, using the DiaSorin Liaison 25-hydroxyvitamin D TOTAL assay. Age (median 67 years), gender (male/female: 675/558), BMI (<18.5/18.5-25/>25/unknown: 96/663/356/118), Performance status (PS) (0/1/2 + 3/unknown: 422/498/135/177) and stage (I+II/III+IV/unknown: 408/758/67) were retrieved. Survival was estimated in three S-25(OH)D groups as: insufficient <25 nmol/L, relatively insufficient 25-50 nmol/L and sufficient >50 nmol/L. For survival analysis, Kaplan-Meier plots, log-rank tests and the Cox regression model were used.

Results

Table:

699P

Stage	I+II	III+IV
S-25(OH)D levels	Pt, No.	mOS, months	95%CI	Pt, No.	mOS, months	95%CI
Sufficient	205	26.2	21.2-34.1	383	7.2	6.2-8.1
Relatively insufficient	156	22.9	18.3-27.8	275	6.3	5.3-7.2
Insufficient	47	15.7	11.3-30.2	100	5.3	3.7-6.4

Abbreviations: Pt, No.: Patient number, mOS: median overall survival, CI: Confidence interval. Overall survival between the three S-25(OH)D groups in stages I and II, log rank p = 0.03, as well as in stages III and IV, log rank p = 0.02, were significantly different. In the multivariate Cox regression analysis, patients with sufficient S-25(OH)D levels had longer survival than those with insufficient levels (HR = 0.77, 95% CI 0.62-0.96; p = 0.02). PS 0 vs. 1 and vs. 2 + 3 (p < 0.01) and tumour stage I+II vs. III+IV (p < 0.01) were also associated with longer survival whereas age, gender and BMI were not.

Conclusions

Patients with PC and sufficient pre-treatment serum 25-hydroxyvitamin D levels had significantly longer OS than those with insufficient levels across all stages.

Clinical trial identification

NCT03311776.

Editorial acknowledgement

Legal entity responsible for the study

Julia Sidenius Johansen.

Funding

Axel Muusfeldt’s Foundation.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

29 Sep 2019